UCB has announced its acquisition of Candid Therapeutics, a company that develops antibody treatments for autoimmune diseases, amid broader biotech updates including funding for gene therapy and challenges posed by China's tightening of pharmaceutical supply chains. Additionally, stricter U.S. immigration policies are reportedly driving international researchers away, impacting the country's scientific talent pool.
China's tightening grip on its pharmaceutical supply chains could pose significant challenges for Western biopharma companies, potentially impacting the availability and cost of essential components. For someone tracking healthtech and biotech developments, this indicates a critical need to assess supply chain resilience and explore alternative sourcing strategies to mitigate potential disruptions.